Home
About Us
News
Archive
Products
Specials Service
Ordering
Business Development
Investor Relations
AIM Rules Compliance (Rule 26)
Contact Us
Sitemap
News
Archive
Previous news can be viewed below.
News
Nov 07
Investing for Growth
(www.investing-for-growth.co.uk)
Nov 07
Growth Company Investor
Jun 07
Investing for Growth
(www.investing-for-growth.co.uk)
Apr 07
Investing for Growth
(www.investing-for-growth.co.uk)
Apr 07
Sunday Times
Sep 06
Peter Shearlock's Small Cap Stock Picks
Jan 06
Share Purchase by Director
RNS Announcements
27/07/10
Result of AGM
27/07/10
AGM Statement
27/07/10
AGM Statement
02/07/10
Posting of Annual Report and Notice of AGM
02/06/10
Preliminary Results
21/04/10
Close Period Trading Update
22/03/10
Sale of Volplex and Isoplex
04/03/10
IS Pharma acquires exclusive European rights for Episil
®
11/01/10
IS Pharma granted exclusive license and supply rights for Aequasyal
®
(oxidised glycerol triester) in the UK
23/11/09
Variquel
®
(Haemopressin
®
) Update
11/11/09
Notice of Interim Results for the six months ended 30 September 2009
10/11/09
Notification of Major Interests in Shares
01/10/09
Pre‐Close Statement
01/09/09
Repurchase of Deferred Ordinary Shares
07/08/09
Director Shareholding
31/07/09
AGM Statement
31/07/09
Result of AGM
31/07/09
Committee membership
28/07/09
Audit and Remuneration Committee Membership Final
28/07/09
Result of AGM
06/07/09
Annual Reports and Accounts and Notice of AGM
30/06/09
30/06/09
Total Voting Rights
22/06/09
Launch of Variquel™ (Haemopressin
®
)
18/06/09
FDA accepts final section of NDA filing for Lucassin
03/06/09
Preliminary Results
21/05/09
Change of Nominated Adviser and Broker
13/05/09
Preliminary Results Announcement
07/05/09
Directorate appointment
16/03/09
Haemopressin MRP Announcement
13/01/09
Directorate changes
03/11/08
Isoplex Launch
14/10/08
Notice of Interim Results
12/09/08
Result of AGM 2008
10/09/08
AGM Statement 2008
03/09/08
US Commercialisation Partner for Haemopressin
03/09/08
Trading Update
18/08/08
Notice of AGM
15/08/08
Notification of Interest
31/07/08
Grant of Options
03/06/08
Preliminary results for the year ended 31 March 2008
30/05/08
Cancellation of Share Premium Account
29/05/08
Notification of Results
22/05/08
Notification of interest
06/05/08
Notification of Interest
02/05/08
Notification of Interest
30/04/08
Notification of Interest
28/04/08
Completion of Acquisition Speciality European Pharma International AG
22/04/08
Directors Dealings
22/04/08
Consolidation and Placing
21/04/08
Result of General Meeting
28/03/08
Acquisition of Speciality European Pharma International AG
11/02/08
Aloxi Launch
13/12/07
Notification of Interest
23/11/07
Investing for Growth
(www.investing-for-growth.co.uk)
13/11/07
Growth Company Investor
06/11/07
Interim results - Maelor transformed to deliver results ahead of expectations
06/11/07
Chief Executive stock purchase
31/10/07
New Distribution Agreement
29/10/07
Aloxi® License Agreement
25/10/07
Notice of Interim Results
25/10/07
Notice of Interim Results
17/09/07
Annual Report and Accounts
05/09/07
Result of AGM
05/09/07
AGM Statement
15/08/07
Rule 26 Compliance
10/08/07
Notice of AGM
10/08/07
Notification of Interest
28/06/07
Change of accounting reference date
22/06/07
Launch of Variquel™ (Haemopressin
®
)
18/06/07
Investing for Growth
(www.investing-for-growth.co.uk)
05/06/07
Maelor results ahead of expectations - profitable in H2
25/05/07
Notification of Interest
22/05/07
Director dealings
22/05/07
Notice of Results
11/05/07
Notification of interest
11/05/07
Notification of interest
10/05/07
Acquisition of Acorus Therapeutics Ltd completed
10/05/07
Director dealings
08/05/07
Director dealings
08/05/07
Re-Admission, Conditional Placing and Acquisition
04/05/07
Result of EGM
20/04/07
Notification of Interest
19/04/07
Maelor PLC - Holding(s) in Company
10/04/07
AIM - Schedule 1 - Maelor plc
05/04/07
Change of Adviser
05/04/07
Acquisition of Acorus Therapeutics Ltd
05/04/07
Pre-Close Statement and Trading update
01/04/07
Investing for Growth
(www.investing-for-growth.co.uk)
01/04/07
Sunday Times
05/03/07
Change of address of Registered Office
22/12/06
Total Voting Rights and Share Capital
19/12/06
Issue of Equity
24/11/06
Interim Report 2006
02/11/06
Interim Results
01/11/06
Appointment of nominated adviser and broker
20/10/06
Notice of Results
14/09/06
Director Dealings
12/09/06
Director Dealings
01/09/06
Peter Shearlock's Small Cap Stock Picks
30/08/06
Grant of Options
02/08/06
AGM Statement
11/07/06
Year End Accounts
01/06/06
Preliminary Results and Strategic Review
01/06/06
Maelor and Plethora Solutions enter into a licensing agreement for micelle nanotechnology
01/06/06
Appointment of new Finance Director
23/02/06
Share Price Announcement
31/01/06
Share Purchase by Director
30/11/05
EGM Results
22/10/05
Interim Accounts
05/10/05
Appointment of new Chief Executive
27/07/05
Annual General Meeting Statement and Acquisition of Product Rights
19/07/05
Maelor Announces Launch of ContiSol
®
in Canada, and Appointment of Exclusive Volplex
®
Distributor in Greece and the Balkans
25/05/05
Maelor plc Preliminary Results
28/04/05
Maelor plc Appoints Geoffrey McMillan as Non-Executive Director
19/04/05
Maelor plc - Appoints AAM Inc. as exclusive ContiSol™ distributors for Canada and the USA
16/12/04
New Nominated Advisor Appointed
01/12/04
Directorate
03/11/04
Maelor plc - Interim Results
28/07/04
Maelor plc Announces New Board Appointment
27/07/04
AGM Statement
21/07/04
Maelor Appoints Volplex
®
Distributor for South Korea
02/06/04
Maelor plc - Preliminary Results
20/05/04
Maelor plc Granted Regulatory Approval for ContiSol™ in Canada
10/05/04
Announcement
15/04/04
Board Statement
30/03/04
Maelor Signs Micelle Technology Agreement
20/03/04
Maelor Receives Volplex
®
Regulatory Approval
24/02/04
Maelor signs significant contract for Volplex
®
in China
18/08/02
FDA ACCEPTS FINAL SECTION OF NDA FILING FOR LUCASSIN
®